{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:13:43Z","timestamp":1762100023618,"version":"3.37.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1124\/dmd.31.3.343","type":"journal-article","created":{"date-parts":[[2003,2,12]],"date-time":"2003-02-12T19:57:36Z","timestamp":1045079856000},"page":"343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Verification of the Selectivity of (+)N-3-Benzylnirvanol as a CYP2C19 Inhibitor"],"prefix":"10.1016","volume":"31","author":[{"given":"Robert L.","family":"Walsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Scott","family":"Obach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.31.3.343_bib1","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0022-3565(24)37719-5","article-title":"Further characterization of the expression in liver and catalytic activity of CYP2B6.","volume":"286","author":"Ekins","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.31.3.343_bib2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12054-8","article-title":"Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.","volume":"28","author":"Faucette","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.3.343_bib3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.3.343_bib4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0090-9556(25)07488-4","article-title":"Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.","volume":"24","author":"Heyn","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.3.343_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2125.2000.00175.x","article-title":"In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.","volume":"49","author":"Ko","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.3.343_bib6","first-page":"853","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.","volume":"25","author":"Ko","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.3.343_bib7","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0090-9556(24)15021-0","article-title":"The role of CYP2C19 in the metabolism of (+\/\u2212) bufuralol, the prototypic substrate of CYP2D6.","volume":"27","author":"Mankowski","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.3.343_bib8","series-title":"Metabolic Drug Interactions","first-page":"29","article-title":"Industrial viewpoint: application of in vitro drug metabolism in various phases of drug development","author":"Ring","year":"2000"},{"key":"10.1124\/dmd.31.3.343_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-Benzylnirvanol and (\u2212)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.3.343_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2125.1995.tb04472.x","article-title":"Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2.","volume":"39","author":"Yoshimoto","year":"1995","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624026321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624026321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.31.3.343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T15:10:12Z","timestamp":1739891412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624026321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S0090955624026321"],"URL":"https:\/\/doi.org\/10.1124\/dmd.31.3.343","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verification of the Selectivity of (+)N-3-Benzylnirvanol as a CYP2C19 Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.31.3.343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}